English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Hepatic steatosis is an increasingly prevalent condition, with estimates of up to 30% amongst western populations. Fatty liver is a common incidental finding on abdominal imaging. Current British Society of Gastroenterology guidelines suggest the use of scoring systems, such as FIB-4 (fibrosis-4) or NFS (non-alcoholic fatty liver disease fibrosis score), to stratify these patients into risk categories for the development of non-alcoholic steatohepatitis, and subsequent liver failure or hepatocellular carcinoma. We carried out an audit of our own practice, to see if these guidelines were being followed. Methods: We interrogated the nat ional imaging management system to identify all scans performed in Wexford general hospital from 16th April to 16th October 2020 which identified “hepatic steatosis” or “fatty liver”. Data extracted included: patient demographics, imaging modality & finding. We correlated this data with the patient’s liver function tests (LFTs) to calculate their FIB-4/ NFS score, and investigated whether suitable patients had been referred to gastroenterology. Results: Of the 145 patient’s identified as having hepatic steatosis on imaging, 65 (44.8%) had ALT derangement, 42 (29%) had alkaline phosphatase (ALP) derangement, 81 (56%) had gamma-glutamyl transpeptidase (GGT) derangement and 23 (16%) had an elevated total bilirubin. Only 26 (17.9%) of these patients had evidence of subsequent liver serology studies, and only 17 (11.7%) had been referred to gastroenterology. None of the patient cohort had either a FIB-4 or NFS score calculated. Conclusions: There is clear evidence that guidelines are not being followed in the management of patients who are incidentally found to have hepatic steatosis.

AB159. SOH21AS135. Incidental hepatic steatosis: are guidelines being followed?